Veloxis Pharms Inc patents expiration
1. Envarsus Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077096 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US9161907 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US10548880 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US9757362 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8617599 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8623410 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US9763920 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8591946 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US7994214 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8889186 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8623411 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8889185 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8586084 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US8486993 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(10 months from now) | |
| US11419823 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(4 years from now) | |
| US11123331 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(4 years from now) | |
| US11110081 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(4 years from now) | |
| US10166190 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(4 years from now) | |
| US10864199 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(4 years from now) | |
| US9549918 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(4 years from now) | |
| US8664239 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(4 years from now) | |
| US8685998 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient
Dosage: TABLET, EXTENDED RELEASE;ORAL
ENVARSUS XR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic